tiprankstipranks
Trending News
More News >
CanadaBis Capital, Inc. (TSE:CANB)
:CANB
Canadian Market

CanadaBis Capital (CANB) AI Stock Analysis

Compare
10 Followers

Top Page

TS

CanadaBis Capital

(CANB)

Rating:51Neutral
Price Target:
C$0.00
▼(-100.00%Downside)
The overall stock score reflects mixed financial performance and bearish technical indicators. While there are positive corporate events supporting future growth, the high valuation and negative cash flows present significant risks. Strategic initiatives and financial improvements are crucial for enhancing the company's market position.

CanadaBis Capital (CANB) vs. iShares MSCI Canada ETF (EWC)

CanadaBis Capital Business Overview & Revenue Model

Company DescriptionCanadaBis Capital, Inc. (CANB) is a Canadian company operating within the cannabis sector. The company is focused on the production and distribution of cannabis products, leveraging its vertically integrated operations to supply both medical and recreational markets. CanadaBis Capital aims to deliver high-quality cannabis products while maintaining a strong commitment to sustainability and innovation.
How the Company Makes MoneyCanadaBis Capital, Inc. generates revenue primarily through the cultivation, production, and sale of cannabis products. The company operates a vertically integrated business model, which means it controls the entire supply chain from cultivation to distribution. This allows CanadaBis to produce various cannabis products, including dried flower, oils, and edibles, for both medical and recreational consumers. Revenue streams include direct sales to consumers, wholesale agreements with dispensaries and retailers, and possibly partnerships with other companies in the cannabis industry to expand its market reach. Additionally, the company's focus on innovation and quality helps it maintain a competitive edge, potentially leading to higher sales and market share.

CanadaBis Capital Financial Statement Overview

Summary
CanadaBis Capital, Inc. is experiencing financial challenges, particularly in terms of cash flow management and profitability. While strengths are seen in gross profit margins and a reasonable equity ratio, the declining revenue, low net profit margin, and negative cash flows indicate a need for strategic adjustments for improved financial health.
Income Statement
52
Neutral
CanadaBis Capital, Inc. shows a mixed performance on the income statement. The gross profit margin for TTM is approximately 47.5%, indicating efficient production cost management relative to revenue. However, the net profit margin is low at 1.1%, reflecting challenges in controlling operating expenses or other costs. Revenue has decreased over the past year, with the most recent TTM revenue at $17.89 million compared to $22.22 million two years prior, showing a negative growth trajectory. EBIT and EBITDA margins are also relatively low, signaling limited operating profitability.
Balance Sheet
65
Positive
The balance sheet presents a moderately stable financial structure. The debt-to-equity ratio for TTM stands at approximately 0.71, which is somewhat high and suggests a reliance on debt financing. The return on equity (ROE) is low at 2.4%, indicating limited efficiency in generating profits from shareholders' equity. However, the equity ratio is at a solid 33%, suggesting a reasonable proportion of assets financed by equity, providing a buffer against liabilities.
Cash Flow
48
Neutral
The cash flow statement reveals challenges in liquidity management. The operating cash flow to net income ratio is negative, as the company reported a negative operating cash flow of -$176,696 for the TTM, indicating difficulties in converting sales to actual cash. Free cash flow is also negative and has decreased over time, from $4.57 million two years ago to -$480,187 in the latest TTM, highlighting cash flow constraints and potential issues with sustaining operations without external funding.
BreakdownTTMSep 2024Sep 2023Sep 2022Sep 2021Sep 2020
Income Statement
Total Revenue17.89M17.95M22.22M11.67M6.87M4.43M
Gross Profit8.50M8.82M11.78M5.57M2.52M1.16M
EBITDA1.64M2.09M5.68M1.63M-1.81M-4.43M
Net Income201.75K600.28K4.44M608.33K-2.68M-5.39M
Balance Sheet
Total Assets25.55M24.55M22.96M15.48M13.28M12.52M
Cash, Cash Equivalents and Short-Term Investments1.33M1.68M3.23M144.88K849.50K167.00K
Total Debt5.95M6.44M7.31M7.82M8.44M6.06M
Total Liabilities17.04M16.45M15.62M12.84M11.46M9.09M
Stockholders Equity8.42M8.00M7.25M2.54M1.73M3.34M
Cash Flow
Free Cash Flow-480.19K-594.48K4.57M-292.54K-1.96M-8.58M
Operating Cash Flow-176.70K-256.31K5.55M-82.77K-1.81M-3.62M
Investing Cash Flow-303.49K-328.33K-965.82K-209.77K122.77K-2.39M
Financing Cash Flow-586.44K-962.02K-1.50M-412.09K2.37M5.85M

CanadaBis Capital Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.04
Price Trends
50DMA
0.05
Negative
100DMA
0.07
Negative
200DMA
0.06
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
43.82
Neutral
STOCH
0.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:CANB, the sentiment is Negative. The current price of 0.04 is below the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.05, and below the 200-day MA of 0.06, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 43.82 is Neutral, neither overbought nor oversold. The STOCH value of 0.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:CANB.

CanadaBis Capital Peers Comparison

Overall Rating
UnderperformOutperform
Sector (67)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
67
Neutral
$17.07B11.919.69%3.75%11.66%-9.47%
51
Neutral
C$5.53M80.000.83%-8.84%-96.82%
51
Neutral
$9.13M-63.75%9.34%69.69%
24
Underperform
$8.45M184.66%125.70%47.09%
* Financial Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:CANB
CanadaBis Capital
0.04
-0.02
-33.33%
TSE:PCLO
PharmaCielo
0.06
-0.10
-64.52%
IMCC
IM Cannabis Corp
2.96
0.83
38.97%

CanadaBis Capital Corporate Events

Business Operations and StrategyFinancial Disclosures
CanadaBis Capital Achieves Positive Q3 2025 Financial Results Amid Market Challenges
Positive
Jul 2, 2025

CanadaBis Capital has reported its financial results for Q3 2025, achieving a positive adjusted EBITDA of $440,665 despite a challenging market environment. The company recorded gross sales of $5.5 million and a 6% increase in gross earnings over previous periods. Strategic cost management and product innovation, including the launch of diamond and Keef-coated pre-rolls, have been pivotal in maintaining operational efficiency. Additionally, CanadaBis has reduced its short-term debt by $2.5 million and plans to launch innovative vape hardware later this year, positioning itself for future growth in the cannabis sector.

M&A TransactionsShareholder Meetings
CanadaBis Capital Ends Arrangement Agreement with Simply Solventless
Negative
Apr 28, 2025

CanadaBis Capital Inc. has terminated its Arrangement Agreement with Simply Solventless Concentrates Ltd., which was intended for SSC to acquire all issued and outstanding shares of CanadaBis. The decision to terminate was due to a ‘Material Adverse Change’ concerning SSC, deemed in the best interest of CanadaBis shareholders and stakeholders. Consequently, all voting and support agreements related to the transaction have been automatically terminated, and a special meeting of CanadaBis shareholders has been canceled.

Private Placements and FinancingBusiness Operations and Strategy
CanadaBis Capital Completes $4 Million Financing to Boost Cannabis Growth
Positive
Apr 14, 2025

CanadaBis Capital Inc. has successfully closed the final tranche of its brokered private placement, raising a total of $4,035,000 through the issuance of unsecured convertible debentures. This financing move, facilitated by Research Capital Corporation, is expected to bolster CanadaBis’s financial position and support its growth strategies in the cannabis industry, particularly in the concentrates segment. The debentures, which mature in 2029, offer a conversion option into common shares, providing flexibility for investors and potentially enhancing shareholder value.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 03, 2025